Cure My Disease

Don't miss your cure!

 Log in / Sign up

New infusion drug hopes to tame rare hormone disorder

NCT ID NCT05669950

Recruiting now Disease control Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called Lu AG13909 in 42 adults with congenital adrenal hyperplasia (CAH), a rare genetic condition that disrupts hormone production. The study aims to check the drug's safety, how it moves through the body, and its effects on hormone levels. Participants receive multiple doses of the drug by infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Lu AG13909 (given as an infusion)

What this could lead to

If successful, this could point toward a new treatment option for congenital adrenal hyperplasia, potentially reducing the need for high doses of steroid replacement therapy.

What could go wrong

This is an early-phase trial with only 42 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero Universitaria di Bologna

    RECRUITING

    Bologna, 40138, Italy

  • Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma

    RECRUITING

    Roma, 00161, Italy

  • Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin

    RECRUITING

    Dublin, D02 YN77, Ireland

  • CHRU Strasbourg

    RECRUITING

    Strasbourg, 67091, France

  • CHU de Lille

    RECRUITING

    Lille, 59000, France

  • Cambridge Clinical Research Centre

    RECRUITING

    Cambridge, CB2 0SL, United Kingdom

  • Centrum Nowoczesnych Terapii, Dobry Lekarz

    RECRUITING

    Dobry Lekarz, 60-324, Poland

  • Chu Angers

    RECRUITING

    Angers, 49933, France

  • David Metreveli Medical Centre, Tbilisi

    RECRUITING

    Tbilisi, 0144, Georgia

  • GH Pitié-Salpêtrière

    RECRUITING

    Paris, 75013, France

  • Karolinska University Hospital

    RECRUITING

    Stockholm, 17174, Sweden

  • NIHR Clinical Research Facility

    RECRUITING

    London, SE1 9RT, United Kingdom

  • NIHR/Wellcome Trust Clinical Research Facility

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, 413 45, Sweden

  • University College London Hospital - NIHR

    RECRUITING

    London, W1T 7HA, United Kingdom

  • University Hospital-University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States